Skip to content

Dyslipidemia management by Mustadi Ghana and lifestyle modification

Etiopathological study of Dyslipidemia and role of Mustadi Ghana and Pathyapalana in its management ââ?¬â?? Single blind Randomized Comparative Clinical Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/05/008627
Enrollment
50
Registered
2017-05-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dyslipidemia (deranged lipid profile) Health Condition 2: I999- Unspecified disorder of circulatory system

Interventions

Intervention1: Group A (Trial group): Mustadi Ghana and Pathyapalana(lifestyle modification) will be given in the patients of Dyslipidemia 4 capsules of 500 mg each once in morning with lukewarm water

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having deranged lipid profile with or without having any symptoms of Sthaulaya/Santarpanjanyavyadhi i.e.Sharirabharvriddhi(overweight) Alasya(fatigue) Gurugatrata(heaviness in body) Aayase shwaskrichhta(dyspnoea) Atikshudha(excessive hunger) Atipipasa(excessive thirst) Swedahikya(excessive perspiration at normal teperature in normal condition) Daurgandhya(bad odor due to perspiration) Daurbalya(weakness) Snigdhangata(oily luster of body) Chal sphikudarstana(movement of some fatty organs like buttocks belly and breast) Sandhishoola(joint pain)

Exclusion criteria

Exclusion criteria: Age less than 30 years and more than 60 years tuberculosis diabetes IHD patients with history of MI within past 6 months hypothyroidism drug induced hyperlipidemia pregnant and lactating woman

Design outcomes

Primary

MeasureTime frame
Efficacy of Mustadi Ghana and Pathyapalana(lifestyle modification)in DyslipdemiaTimepoint: 12 weeks

Secondary

MeasureTime frame
Safety of Mustadi Ghana in DyslipidemiaTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Darshna Pandya

IPGT and RA

darshnapandya@rediffmail.com09099011095

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026